Clinical Trials | January 08, 2026
Alumis reports breakthrough Phase 3 results for oral psoriasis therapy
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The combination also outperformed chemotherapy on another important secondary endpoint
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
Subscribe To Our Newsletter & Stay Updated
